Initial investment phase
Initial investment size
€500k to €2.5m
Partnering with the best.
Blueprint Genetic supports health care professionals worldwide in finding the best care for patients and families with rare inherited diseases through AI-enabled clinical genetic DNA testing.
CryoTherapeutics develops a revolutionary cardiovascular catheter system for the treatment of unstable non-stenotic lesions in coronary heart vessels, thereby significantly reducing the need for stenting.
Klara is the secure healthcare communication platform, revolutionizing healthcare communication for everyone involved in the patient's journey.
Phenex is a world-renowned drug discovery and development company focused on the target class of nuclear receptors for the development of novel pharmaceuticals.
Prostatype Genemocs develops and commercializes the molecular diagnostic test “Prostatype™” to stratify prostate cancer patients into risk categories and provide decision support when making a treatment decision.
SIRION is a supplier of sophisticated viral vectors that are being used for gene function research, preclinical target validation, gene therapy and vaccine development.
Updates and opinions.
CEVEC closes growth financing round to serve strong demand in viral vector technologies for cell and gene therapies
July 28, 2021
Successful Exit for Creathor Ventures, High-Tech Gründerfonds, Bayern Kapital and KfW– PerkinElmer agrees to acquire Viral Vector Gene Delivery Leader SIRION Biotech
June 23, 2021
Bad homburg — zUrich
Putting our expertise and experience to work for your success.